492 related articles for article (PubMed ID: 25260226)
1. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
Bryan LJ; Gordon LI
Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
[TBL] [Abstract][Full Text] [Related]
2. [Immune-checkpoint inhibitors in hematologic malignancies].
Maruyama D
Rinsho Ketsueki; 2016; 57(11):2381-2387. PubMed ID: 27941289
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
4. Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies.
Bryan LJ; Gordon LI
Oncology (Williston Park); 2015 Jun; 29(6):431-9. PubMed ID: 26091677
[TBL] [Abstract][Full Text] [Related]
5. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
6. Clinical Development of PD-1 Blockade in Hematologic Malignancies.
Pianko MJ; Goldberg AD; Lesokhin AM
Cancer J; 2018; 24(1):31-35. PubMed ID: 29360725
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.
Jelinek T; Mihalyova J; Kascak M; Duras J; Hajek R
Immunology; 2017 Nov; 152(3):357-371. PubMed ID: 28685821
[TBL] [Abstract][Full Text] [Related]
8. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies.
Janakiram M; Pareek V; Cheng H; Narasimhulu DM; Zang X
Immunotherapy; 2016 Jun; 8(7):809-19. PubMed ID: 27349980
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
11. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
12. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
Ansell SM
J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for checkpoint inhibition in hematologic malignancies.
Atanackovic D; Luetkens T
Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
[TBL] [Abstract][Full Text] [Related]
14. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer.
Henick BS; Herbst RS; Goldberg SB
Expert Opin Ther Targets; 2014 Dec; 18(12):1407-20. PubMed ID: 25331677
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade in lymphoid malignancies.
Thanarajasingam G; Thanarajasingam U; Ansell SM
FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
[TBL] [Abstract][Full Text] [Related]
16. Pidilizumab in the treatment of diffuse large B-cell lymphoma.
Bryan LJ; Gordon LI
Expert Opin Biol Ther; 2014 Sep; 14(9):1361-8. PubMed ID: 25056108
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-1-targeted therapies focusing on lymphatic malignancies: biological rationale, clinical challenges and opportunities.
Kedmi M; Avigdor A; Nagler A
Acta Haematol; 2015; 133(2):129-35. PubMed ID: 25247668
[TBL] [Abstract][Full Text] [Related]
18. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system.
Nastoupil LJ; Neelapu SS
Curr Oncol Rep; 2015 Jul; 17(7):30. PubMed ID: 25986722
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
Bröckelmann PJ; Engert A
Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424
[TBL] [Abstract][Full Text] [Related]
20. Targeting immune checkpoints in lymphoma.
Ansell SM
Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
